Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version).
Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. Shimada A, et al. Among authors: imagawa a. Diabetol Int. 2024 Jan 8;15(1):1-4. doi: 10.1007/s13340-023-00679-1. eCollection 2024 Jan. Diabetol Int. 2024. PMID: 38264233
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Kurozumi A, Hatazaki M, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Kato K, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Cardiovasc Diabetol. 2023 Jun 22;22(1):143. doi: 10.1186/s12933-023-01879-4. Cardiovasc Diabetol. 2023. PMID: 37349722 Free PMC article. Clinical Trial.
New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version).
Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. Shimada A, et al. Among authors: imagawa a. J Diabetes Investig. 2024 Feb;15(2):254-257. doi: 10.1111/jdi.14121. Epub 2024 Jan 7. J Diabetes Investig. 2024. PMID: 38184802 Free PMC article.
Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report.
Mitsuya S, Arai M, Kanaoka K, Funamoto T, Tsuji H, Tsuruoka K, Matsunaga N, Nakamura T, Tamura Y, Imanishi M, Ikeda S, Imagawa A, Fujisaka Y. Mitsuya S, et al. Among authors: imagawa a. JTO Clin Res Rep. 2024 Jan 5;5(2):100631. doi: 10.1016/j.jtocrr.2024.100631. eCollection 2024 Feb. JTO Clin Res Rep. 2024. PMID: 38322711 Free PMC article.
Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial. Mita T, et al. Diabetes Care. 2016 Jan;39(1):139-48. doi: 10.2337/dc15-0781. Epub 2015 Dec 1. Diabetes Care. 2016. PMID: 26628419 Clinical Trial.
Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Watada H, Shimomura I; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis Trial. Katakami N, et al. J Atheroscler Thromb. 2013;20(12):893-902. doi: 10.5551/jat.18333. Epub 2013 Aug 20. J Atheroscler Thromb. 2013. PMID: 23965491 Free article. Clinical Trial.
315 results